Price T Rowe Associates Inc Repligen Corp Transaction History

Price T Rowe Associates Inc

  • $883 Billion
  • Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,603,954 shares of RGEN stock, worth $802 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
6,603,954
Previous 7,566,093 12.72%
Holding current value
$802 Million
Previous $963 Million 14.68%
% of portfolio
0.09%
Previous 0.12%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$108.89 - $145.23 $105 Million - $140 Million
-962,139 Reduced 12.72%
6,603,954 $821 Million
Q1 2025

May 14, 2025
BUY
$127.24 - $174.24 $54.7 Million - $74.9 Million
430,039 Added 6.03%
7,566,093 $963 Million
Q4 2024

Feb 14, 2025
BUY
$123.41 - $160.92 $91.8 Million - $120 Million
743,815 Added 11.64%
7,136,054 $1.03 Billion
Q3 2024

Nov 14, 2024
BUY
$119.79 - $167.35 $214 Million - $299 Million
1,783,806 Added 38.71%
6,392,239 $951 Million
Q2 2024

Aug 14, 2024
BUY
$120.0 - $182.95 $125 Million - $190 Million
1,040,117 Added 29.15%
4,608,433 $581 Million
Q1 2024

May 15, 2024
SELL
$170.78 - $208.42 $75.5 Million - $92.1 Million
-441,939 Reduced 11.02%
3,568,316 $656 Million
Q4 2023

Feb 14, 2024
BUY
$114.17 - $185.35 $23.8 Million - $38.6 Million
208,413 Added 5.48%
4,010,255 $721 Million
Q3 2023

Nov 14, 2023
BUY
$138.78 - $176.51 $11.8 Million - $15 Million
85,077 Added 2.29%
3,801,842 $605 Million
Q2 2023

Aug 14, 2023
SELL
$138.42 - $180.31 $6.23 Million - $8.12 Million
-45,033 Reduced 1.2%
3,716,765 $526 Million
Q1 2023

May 15, 2023
SELL
$154.26 - $198.1 $202 Million - $259 Million
-1,308,859 Reduced 25.81%
3,761,798 $633 Million
Q4 2022

Feb 14, 2023
BUY
$162.42 - $220.56 $229 Million - $311 Million
1,411,078 Added 38.56%
5,070,657 $859 Million
Q3 2022

Nov 14, 2022
SELL
$160.42 - $256.21 $300 Million - $480 Million
-1,871,942 Reduced 33.84%
3,659,579 $685 Million
Q2 2022

Aug 15, 2022
BUY
$140.68 - $188.02 $247 Million - $330 Million
1,755,417 Added 46.49%
5,531,521 $898 Million
Q1 2022

May 16, 2022
BUY
$161.19 - $257.96 $118 Million - $189 Million
733,449 Added 24.11%
3,776,104 $710 Million
Q4 2021

Feb 14, 2022
BUY
$247.59 - $304.47 $183 Million - $224 Million
737,206 Added 31.98%
3,042,655 $806 Million
Q3 2021

Nov 15, 2021
BUY
$194.77 - $324.21 $107 Million - $178 Million
550,303 Added 31.35%
2,305,449 $666 Million
Q2 2021

Aug 16, 2021
BUY
$165.87 - $220.95 $72.3 Million - $96.3 Million
435,972 Added 33.05%
1,755,146 $350 Million
Q1 2021

May 17, 2021
BUY
$180.37 - $226.26 $23.6 Million - $29.6 Million
130,709 Added 11.0%
1,319,174 $256 Million
Q4 2020

Feb 16, 2021
BUY
$148.08 - $206.57 $176 Million - $246 Million
1,188,465 New
1,188,465 $228 Million

Others Institutions Holding RGEN

# of Institutions
502
Shares Held
58.2M
Call Options Held
89.3K
Put Options Held
679K
View Full List

About REPLIGEN CORP

RGEN Quotes by TradingView
  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.74B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email